Kymera Therapeutics Stock Total Asset
| KYMR Stock | USD 46.86 0.88 1.91% |
Kymera Therapeutics fundamentals help investors to digest information that contributes to Kymera Therapeutics' financial success or failures. It also enables traders to predict the movement of Kymera Stock. The fundamental analysis module provides a way to measure Kymera Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kymera Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 575.8 M | 446 M |
Kymera | Total Asset |
Kymera Therapeutics Company Total Asset Analysis
Kymera Therapeutics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Kymera Therapeutics Total Asset | 575.76 M |
Most of Kymera Therapeutics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kymera Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Kymera Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Kymera Therapeutics is extremely important. It helps to project a fair market value of Kymera Stock properly, considering its historical fundamentals such as Total Asset. Since Kymera Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kymera Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kymera Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Kymera Total Asset Historical Pattern
Today, most investors in Kymera Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Kymera Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Kymera Therapeutics total asset as a starting point in their analysis.
Kymera Therapeutics Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Kymera Total Assets
Total Assets |
|
Based on the latest financial disclosure, Kymera Therapeutics has a Total Asset of 575.76 M. This is 92.34% lower than that of the Biotechnology sector and 70.86% lower than that of the Health Care industry. The total asset for all United States stocks is 98.05% higher than that of the company.
Kymera Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kymera Therapeutics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kymera Therapeutics could also be used in its relative valuation, which is a method of valuing Kymera Therapeutics by comparing valuation metrics of similar companies.Kymera Therapeutics is currently under evaluation in total asset category among its peers.
Kymera Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kymera Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kymera Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Kymera Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Kymera Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kymera Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kymera Therapeutics' value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 M | Rock Springs Capital Management Lp | 2024-06-30 | 1.2 M | Geode Capital Management, Llc | 2024-09-30 | 1.1 M | Jennison Associates Llc | 2024-09-30 | 797.7 K | Deep Track Capital, Lp | 2024-09-30 | 600.3 K | Woodline Partners Lp | 2024-06-30 | 517.8 K | Eventide Asset Management, Llc | 2024-09-30 | 507.9 K | Avidity Partners Management Lp | 2024-09-30 | 500 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 472.6 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 6.4 M | Baker Bros Advisors Lp | 2024-09-30 | 6 M |
Kymera Fundamentals
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.91) % | ||||
| Operating Margin | (19.28) % | ||||
| Current Valuation | 2.52 B | ||||
| Shares Outstanding | 64.77 M | ||||
| Shares Owned By Insiders | 1.27 % | ||||
| Shares Owned By Institutions | 98.73 % | ||||
| Number Of Shares Shorted | 9.12 M | ||||
| Price To Book | 3.33 X | ||||
| Price To Sales | 34.66 X | ||||
| Revenue | 78.59 M | ||||
| Gross Profit | (117.42 M) | ||||
| EBITDA | (143.2 M) | ||||
| Net Income | (146.96 M) | ||||
| Cash And Equivalents | 392.31 M | ||||
| Cash Per Share | 7.61 X | ||||
| Total Debt | 84.67 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 4.60 X | ||||
| Book Value Per Share | 13.79 X | ||||
| Cash Flow From Operations | (102.83 M) | ||||
| Short Ratio | 22.84 X | ||||
| Earnings Per Share | (2.34) X | ||||
| Price To Earnings To Growth | 0.64 X | ||||
| Target Price | 57.76 | ||||
| Number Of Employees | 184 | ||||
| Beta | 2.22 | ||||
| Market Capitalization | 3.03 B | ||||
| Total Asset | 575.76 M | ||||
| Retained Earnings | (530.75 M) | ||||
| Working Capital | 319.63 M | ||||
| Net Asset | 575.76 M |
About Kymera Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kymera Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kymera Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kymera Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Kymera Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Kymera Stock
The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.
The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.